Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Kidney Blood Flow During Open Aortic Surgery (RENAL-SHUNT) (RENAL-SHUNT)

15. november 2026 opdateret af: Rodolfo Pini, University of Bologna

Prospective Observational Evaluation of Temporary Selective Renal Blood Perfusion During Open Aortic Surgery With Suprarenal Cross-Clamping

During some operations on the abdominal aorta, the surgeon needs to temporarily clamp the aorta above the arteries that supply the kidneys. This can reduce blood flow to the kidneys and may cause acute kidney injury.

This study will follow 50 adults at Policlinico di Sant'Orsola in Bologna, Italy. During their operation, a temporary shunt will perfuse blood from humeral artery to the renal arteries. The treating surgeon decides whether to use the shunt as part of clinical care, independently of study participation.

The researchers will record how often kidney injury occurs in the first 7 days after surgery and how often problems related to the shunt, kidney arteries or arm access occur within 30 days. They will also track the need for dialysis, kidney function and survival over 12 months.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Detaljeret beskrivelse

RENAL-SHUNT is a single-center prospective observational registry of adults undergoing open abdominal aortic reconstruction requiring suprarenal or supravisceral cross-clamping. The surgical team may select passive renal blood perfusion when it anticipates prolonged or uncertain renal ischemia or considers the patient at high renal risk. The study observes a single exposed cohort. Treatment decisions are made independently of enrollment.

The registry will record baseline kidney function and preoperative acute kidney injury, aortic pathology, urgency, clamp level, periods of renal ischemia and perfusion, hemodynamics, transfusion and complications. Serum creatinine will be collected from routine postoperative assessments where available. Recorded urine output will be used for Kidney Disease: Improving Global Outcomes (KDIGO) classification when available. Follow-up assessments include discharge and postoperative days 30 and 90 and months 6 and 12.

The study targets 50 consecutive participants based on expected accrual over up to 5 years. Event rates will be presented as counts and percentages with 95% confidence intervals. At an observed rate of 20% (10 of 50), the Wilson 95% confidence interval would be approximately 11% to 33%. Changes in serum creatinine and estimated glomerular filtration rate will be summarized from baseline. Subgroup and longitudinal analyses will be exploratory.

The investigators will maintain a screening log and collect data in a coded electronic case report form with a data dictionary and prespecified time windows. Range, consistency and missing-data checks will be completed before database lock. Two investigators will review acute kidney injury stage, major adverse kidney events and serious technique-related events when feasible. Available denominators will be reported for each outcome. The primary outcome will use observed data, with a creatinine-only analysis when urine-output records are incomplete.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

50

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Adults undergoing open abdominal aortic reconstruction with suprarenal or supravisceral cross-clamping at Policlinico di Sant'Orsola in Bologna, Italy, for whom the surgical team selects temporary renal blood perfusion.

Beskrivelse

Inclusion Criteria:

  1. Age 18 years or older.

  2. Open abdominal aortic reconstruction requiring suprarenal or supravisceral cross-clamping.

  3. Independent clinical decision by the treating surgeon to use the described renal perfusion circuit.

  4. At least one renal artery intended for shunt perfusion.

  5. Written informed consent before surgery through the approved process.

    Exclusion Criteria:

  6. Maintenance kidney replacement therapy before surgery.

  7. No initiation of renal shunt perfusion after consent.

  8. Inability or unwillingness to provide informed consent under the approved process.

  9. Pregnancy.

  10. Primary renal perfusion using cardiopulmonary bypass or a dedicated visceral perfusion system.

  11. Clinical contraindication to brachial access or renal ostial cannulation.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Postoperative acute kidney injury
Tidsramme: End of surgery through postoperative day 7

Number and percentage of participants meeting KDIGO 2012 criteria. Acute kidney injury is defined by a serum creatinine rise of at least 0.3 mg/dL within 48 hours, serum creatinine at least 1.5 times the reference within 7 days, or urine output below 0.5 mL/kg/hour for at least 6 hours. Reference creatinine is the most recent stable value 7 to 90 days before surgery, or the preoperative value if a stable historical value is unavailable. Cases with preoperative acute kidney injury will be adjudicated and described separately.

End of surgery through postoperative day 7

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

1. december 2028

Studieafslutning (Anslået)

1. december 2031

Datoer for studieregistrering

Først indsendt

15. november 2026

Først indsendt, der opfyldte QC-kriterier

15. november 2026

Først opslået (Faktiske)

20. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner